obesity – Page 3

Examining the Link Between Obesity and Kidney Outcomes in Heart Failure with Preserved Ejection Fraction

By MedXY 08/11/2025

A pooled analysis of four heart failure trials explores the relationship between obesity and kidney outcomes, revealing waist circumference and waist-to-height ratio as key risk factors, while body mass index showed no significant association.

Cardiology Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

By MedXY 08/09/2025

A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Three Weeks of Ketogenic Diet Significantly Boosts Skeletal Muscle Insulin Sensitivity in Obesity: Insights from a Randomized Crossover Trial

By MedXY 08/08/2025

A 3-week ketogenic diet improved skeletal muscle insulin sensitivity and promoted weight loss in individuals with obesity, without significant effects on liver or adipose tissue insulin sensitivity.

Cardiology Clinical Updates Family Medicine & Nutrition news Specialties

Ketogenic vs. Mediterranean Diets in Overweight Hypertensive Patients: Insights from the Keto-Salt Pilot Study

By MedXY 08/08/2025

A head-to-head comparison of ketogenic and Mediterranean diets demonstrates comparable benefits on weight, blood pressure, and metabolic health in overweight hypertensive adults over three months.

Cardiology Diabetes & Endocrinology news Specialties

Effect of a Ketogenic Diet, Time-Restricted Eating, or Alternate-Day Fasting on Weight Loss in Adults with Obesity: A Randomized Clinical Trial

By MedXY 08/08/2025

This clinical trial compares the weight loss effects of ketogenic diet, time-restricted eating, and alternate-day fasting against a Mediterranean diet in adults with obesity over three months.

Clinical Updates Diabetes & Endocrinology news Respiratory Specialties

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

By MedXY 08/08/2025

Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Personalized Probiotic Therapy: Akkermansia muciniphila Supplementation in Overweight and Obese Type 2 Diabetes—Baseline Levels Matter

By MedXY 08/08/2025

Akkermansia muciniphila supplementation improves metabolic outcomes in overweight/obese type 2 diabetes patients only when baseline gut levels are low, underscoring the need for personalized microbiota-guided interventions.

Family Medicine & Nutrition Internal Medicine news Specialties

How High-Fiber Diets and Supplements Can Improve Health for Patients With Obesity

By MedXY 08/06/2025

High-fiber diets and supplements can aid weight management, improve metabolic health, and reduce obesity-related risks by enhancing digestion, promoting satiety, and regulating blood sugar levels.

Clinical Updates Diabetes & Endocrinology news Specialties

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

By MedXY 08/05/2025

Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.

Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

By MedXY 08/03/2025

Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.

Clinical Updates Diabetes & Endocrinology news Specialties

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

By MedXY 08/02/2025

Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.

Diabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

Medical News news Oncology Specialties

Obesity-Linked Liver Cancer: A Preventable Crisis on the Rise

By MedXY 07/31/2025

Over 60% of liver cancer cases are preventable, yet rising obesity and metabolic dysfunction threaten progress. The Lancet Commission outlines urgent strategies to curb a projected doubling of global liver cancer burden by 2050.

Cardiology Diabetes & Endocrinology Medical News news Specialties

Redefining Obesity: Impact of the ‘Clinical Obesity’ Framework on Global Prevalence Estimates

By MedXY 07/30/2025

A new, function-driven definition of “clinical obesity” dramatically lowers global obesity prevalence rates compared to BMI-based estimates, raising implications for disease surveillance, prevention, and healthcare policy.

Cardiology Diabetes & Endocrinology news Specialties

Understanding Macronutrients: Their Role in Obesity and Weight Management

By MedXY 07/29/2025

Explore the impact of macronutrients on obesity, focusing on carbohydrates, proteins, and fats, and learn strategies for effective weight management.

Diabetes & Endocrinology news Specialties

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

By MedXY 07/28/2025

Semaglutide drugs like Ozempic and Wegovy are transforming obesity treatment, but questions remain about long-term safety, access, and societal impact.

news

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

By MedXY 07/28/2025

Exploring the science, benefits, risks, and realities behind Ozempic and other GLP-1 drugs in the fight against obesity.

Diabetes & Endocrinology news

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.

Diabetes & Endocrinology news Specialties

Unraveling the Gut-Brain Connection: How Our Brain Detects Glucose

By MedXY 07/25/2025

Scientists at KAIST have identified a unique gut-brain pathway that enables the brain to distinguish glucose from other nutrients, paving the way for novel treatments for metabolic disorders.

Diabetes & Endocrinology Infectious Diseases news

Impact of Obesity on Long COVID: Insights from Primate Studies

By MedXY 07/25/2025

Obesity influences the long-term effects of SARS-CoV-2, revealing diverse outcomes in primates and suggesting broader implications for humans.